East China Pharmaceutical: Clinical trial for injection DR30206 approved.

East China Pharmaceutical announced that its controlling subsidiary, Zhejiang Daor Biological Technology Co., Ltd., has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its application of clinical trials for the injectable DR30206. Injectable DR30206 is a fusion protein antibody targeting PD-L1, VEGF, and TGF-, intended for use in patients with locally advanced or metastatic non-small cell lung cancer. The completed non-clinical studies and ongoing Phase I clinical trial results have demonstrated good safety and tumor growth inhibition. The approval of this clinical trial is an important milestone in the development of new drugs and will not have a significant impact on the company's recent performance.